SCHEMBL2748946

SCHEMBL2748946

O=S(=O)(Oc1cc2c(F)ccc(F)c2cn1)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.38
PDE4C Q08493 3/20 0.38
PDE4D Q08499 3/20 0.38
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
KIF11 P52732 1/20 0.32
HTT P42858 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
TET2 Q6N021 3/20 0.31
ESR2 Q92731 1/20 0.30
MEN1 O00255 1/20 0.30
PABPC1 P11940 1/20 0.30
KMT2A Q03164 1/20 0.30
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2749219 0.90 PDE4A (0.34) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL2749357 0.90 PDE4A (0.34) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL2748184 0.90 PDE4A (0.39) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL2748657 0.87 SLC22A12 (0.38) PDE4APDE4CPDE4D
SCHEMBL2749108 0.82 PDE4A (0.35) PDE4APDE4CPDE4D
SCHEMBL743925 0.81 PDE4A (0.38) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL2749443 0.80 PDE4A (0.43) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL20517546 0.80 PDE4A (0.38) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL30600901 0.80 PDE4A (0.38) PDE4APDE4CPDE4DHTR1AHTR1D
SCHEMBL2748521 0.80 PDE4A (0.34) PDE4APDE4CPDE4DHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 PDE4A 2821/4885PDE4C 3015/4885PDE4D 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.